Page last updated: 2024-08-24

imiquimod and antimony

imiquimod has been researched along with antimony in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dowlati, Y; Eskandari, SE; Firooz, A; Ghoorchi, MH; Gorouhi, F; Hooshmand, B; Khamesipour, A; Khatami, A; Nassiri-Kashani, M; Rashighi-Firoozabadi, M	1
Minodier, P; Parola, P	1
Calderon, W; Cruz, M; Gyorkos, TW; Llanos-Cuentas, A; Matlashewski, G; Miranda-Verastegui, C; Rahme, E; Tulliano, G; Ward, B	1

Reviews

1 review(s) available for imiquimod and antimony

Article	Year
Cutaneous leishmaniasis treatment. Travel medicine and infectious disease, 2007, Volume: 5, Issue:3 Topics: Administration, Cutaneous; Administration, Oral; Aminoquinolines; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Humans; Imiquimod; Injections, Intralesional; Injections, Intramuscular; Leishmaniasis, Cutaneous; Paromomycin; Pentamidine; Phosphorylcholine	2007

Trials

2 trial(s) available for imiquimod and antimony

Article	Year
Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Archives of dermatology, 2006, Volume: 142, Issue:12 Topics: Adjuvants, Immunologic; Adolescent; Adult; Aminoquinolines; Animals; Antimony; Antiprotozoal Agents; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imiquimod; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Single-Blind Method; Treatment Outcome	2006
First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS neglected tropical diseases, 2009, Jul-28, Volume: 3, Issue:7 Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimony; Antiprotozoal Agents; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imiquimod; Immunologic Factors; Leishmaniasis, Cutaneous; Male; Middle Aged; Peru; Toll-Like Receptor 7; Treatment Outcome; Young Adult	2009

Article

Year

Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.

Archives of dermatology, 2006, Volume: 142, Issue:12

Topics: Adjuvants, Immunologic; Adolescent; Adult; Aminoquinolines; Animals; Antimony; Antiprotozoal Agents; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imiquimod; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Single-Blind Method; Treatment Outcome

2006

First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

PLoS neglected tropical diseases, 2009, Jul-28, Volume: 3, Issue:7

Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimony; Antiprotozoal Agents; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imiquimod; Immunologic Factors; Leishmaniasis, Cutaneous; Male; Middle Aged; Peru; Toll-Like Receptor 7; Treatment Outcome; Young Adult

2009